202 related articles for article (PubMed ID: 35650195)
1. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma.
Lamhamedi-Cherradi SE; Maitituoheti M; Menegaz BA; Krishnan S; Vetter AM; Camacho P; Wu CC; Beird HC; Porter RW; Ingram DR; Ramamoorthy V; Mohiuddin S; McCall D; Truong DD; Cuglievan B; Futreal PA; Velasco AR; Anvar NE; Utama B; Titus M; Lazar AJ; Wang WL; Rodriguez-Aguayo C; Ratan R; Livingston JA; Rai K; MacLeod AR; Daw NC; Hayes-Jordan A; Ludwig JA
Nat Commun; 2022 Jun; 13(1):3057. PubMed ID: 35650195
[TBL] [Abstract][Full Text] [Related]
2. Enzalutamide induces cytotoxicity in desmoplastic small round cell tumor independent of the androgen receptor.
Magrath JW; Goldberg IN; Truong DD; Hartono AB; Sampath SS; Jackson CE; Ghosh A; Cardin DL; Zhang H; Ludwig JA; Lee SB
Commun Biol; 2024 Apr; 7(1):411. PubMed ID: 38575753
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide Induces Cytotoxicity in Desmoplastic Small Round Cell Tumor Independent of the Androgen Receptor.
Magrath JW; Goldberg IN; Truong DD; Hartono AB; Sampath SS; Jackson CE; Ghosh A; Cardin DL; Zhang H; Ludwig JA; Lee SB
bioRxiv; 2023 Nov; ():. PubMed ID: 37986851
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
6. Antagonistic action of a synthetic androgen ligand mediated by chromatin remodeling in a human prostate cancer cell line.
Sawada T; Kanemoto Y; Amano R; Hayakawa A; Kurokawa T; Mori J; Kato S
Biochem Biophys Res Commun; 2022 Jul; 612():110-118. PubMed ID: 35523048
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.
Ogura K; Somwar R; Hmeljak J; Magnan H; Benayed R; Momeni Boroujeni A; Bowman AS; Mattar MS; Khodos I; de Stanchina E; Jungbluth A; Asher M; Odintsov I; Hartono AB; LaQuaglia MP; Slotkin E; Pratilas CA; Lee SB; Spraggon L; Ladanyi M
Clin Cancer Res; 2021 Feb; 27(4):1184-1194. PubMed ID: 33229458
[TBL] [Abstract][Full Text] [Related]
8. Androgens induce divergent proliferative responses in human breast cancer cell lines.
Birrell SN; Bentel JM; Hickey TE; Ricciardelli C; Weger MA; Horsfall DJ; Tilley WD
J Steroid Biochem Mol Biol; 1995 May; 52(5):459-67. PubMed ID: 7748811
[TBL] [Abstract][Full Text] [Related]
9. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding.
Zhu Z; Shi M; Hu W; Estrella H; Engebretsen J; Nichols T; Briere D; Hosea N; Los G; Rejto PA; Fanjul A
BMC Genomics; 2012 Jul; 13():355. PubMed ID: 22849360
[TBL] [Abstract][Full Text] [Related]
11. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
12. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
13. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
Dalal K; Roshan-Moniri M; Sharma A; Li H; Ban F; Hessein M; Hsing M; Singh K; LeBlanc E; Dehm S; Tomlinson Guns ES; Cherkasov A; Rennie PS
J Biol Chem; 2014 Sep; 289(38):26417-26429. PubMed ID: 25086042
[TBL] [Abstract][Full Text] [Related]
14. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
[TBL] [Abstract][Full Text] [Related]
15. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
[TBL] [Abstract][Full Text] [Related]
16. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
17. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
18. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
[TBL] [Abstract][Full Text] [Related]
19. Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy.
Fine RL; Shah SS; Moulton TA; Yu IR; Fogelman DR; Richardson M; Burris HA; Samuels BL; Assanasen C; Gorroochurn P; Hibshoosh H; Orjuela M; Garvin J; Goldman FD; Dubovsky D; Walterhouse D; Halligan G
Cancer Chemother Pharmacol; 2007 Mar; 59(4):429-37. PubMed ID: 16896931
[TBL] [Abstract][Full Text] [Related]
20. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells.
Need EF; Selth LA; Harris TJ; Birrell SN; Tilley WD; Buchanan G
Mol Endocrinol; 2012 Nov; 26(11):1941-52. PubMed ID: 23023562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
